ArticlemSphere2024
Emergence of KPC-2 and NDM-5-coproducing hypervirulent carbapenem-resistant
Article in mSphere, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 17 citations in OpenAlex.
- Risk factors for infection in NDM-colonized patients and applicability of the Giannella Risk Score.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Molecular and phenotypic profiles of carbapenem- and third-generation cephalosporin-resistant Klebsiella pneumoniae isolates from the fecal microbiota of pediatric patients with COVID-19.BMC microbiology · 2026Article
- Combinatorial effects of a novel SHV-248 variant, NDM-5, andMicrobiology spectrum · 2026Article
- Emergence and dissemination of extensively drug-resistant ST307Microbial genomics · 2026Article
- Phenotypic and genomic characterization of NDM-producingMicrobiology spectrum · 2026Article
- Article
- Phage-meropenem synergy against OXA-48-producing Klebsiella pneumoniae clinical isolates.npj antimicrobials and resistance · 2026Article
- Genomic and functional characterization of ST11-KL64 hypervirulence-associated carbapenem-resistantFrontiers in microbiology · 2026Article
- Distribution of ST116 carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- Genomic Epidemiology and Antimicrobial Resistance Analyses ofInfection and drug resistance · 2026Article
- Occurrence of KPC-71 or the presence of NDM combined with a high expression ofMicrobiology spectrum · 2025Article
- Significant Prevalence of Dual KPC/NDM Carbapenemase-ProducingAntibiotics (Basel, Switzerland) · 2025Article
- Type I-E* CRISPR-Cas ofmSphere · 2025Article
- Dissemination ofMicrobiology spectrum · 2025Article
- Multispecies emergence of dualAntimicrobial agents and chemotherapy · 2025Article
- Enhanced invasion and survival of antibiotic- resistantFrontiers in cellular and infection microbiology · 2025Article
- Emergence of KPC-2 and NDM-13-coproducing carbapenem-resistant hypervirulentFrontiers in microbiology · 2025Article
- Co-Production of KPC-2 and NDM-5 in a Carbapenem-ResistantInfection and drug resistance · 2025Article
- Transcriptomic Insights into Adaptive Strategies ofInfection and drug resistance · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
The emergence of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.